Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease

Molecular Therapy

Volumn 20, Issue 12, 2012, Pages 2347-2354

  Weng, Jianyu ^a   He, Chang ^b   Lai, Peilong ^a   Luo, Chenwei ^a   Guo, Rong ^a   Wu, Suijing ^a   Geng, Suxia ^a   Xiangpeng, Andy ^c   Liu, Xialin ^b   Du, Xin ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; ATTENUATION; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRY EYE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MALE; MESENCHYMAL STROMA CELL; OCULAR SURFACE DISEASE; PATIENT SAFETY; SCHIRMER TEST; SCORING SYSTEM; SEX DIFFERENCE; T LYMPHOCYTE SUBPOPULATION; TH1 TH2 BALANCE; THERAPY EFFECT; TREATMENT OUTCOME;

EID: 84870606505     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.208     Document Type: Article

References (43)

1. Weng, JY, Du, X, Geng, SX, Peng, YW, Wang, Z, Lu, ZS et al. (2010). Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 45: 1732-1740.
2. Sáles, CS, Johnston, LJ and Ta, CN (2011). Long-term clinical course of dry eye in patients with chronic graft-versus-host disease referred for eye examination. Cornea 30: 143-149.
3. Koch, KR, Joussen, AM and Huber, KK (2011). Ocular involvement in chronic graft-versus-host disease: therapeutic approaches to complicated courses. Cornea 30: 107-113.
4. Mencucci, R, Rossi Ferrini, C, Bosi, A, Volpe, R, Guidi, S and Salvi, G (1997). Ophthalmological aspects in allogenic bone marrow transplantation: Sjögren-like syndrome in graft-versus-host disease. Eur J Ophthalmol 7: 13-18.
5. Ogawa, Y, Okamoto, S, Wakui, M, Watanabe, R, Yamada, M, Yoshino, M et al. (1999). Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol 83: 1125-1130.
6. Ogawa, Y and Kuwana, M (2003). Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea 22(7 Suppl): S19-S27.
7. Filipovich, AH, Weisdorf, D, Pavletic, S, Socie, G, Wingard, JR, Lee, SJ et al. (2005). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11: 945-956.
8. Calissendorff, B, el Azazi, M and Lönnqvist, B (1989). Dry eye syndrome in longterm follow-up of bone marrow transplanted patients. Bone Marrow Transplant 4: 675-678.
9. Khanal, S and Tomlinson, A (2012). Tear physiology in dry eye associated with chronic GVHD. Bone Marrow Transplant 47: 115-119.
10. Ogawa, Y, Okamoto, S, Kuwana, M, Mori, T, Watanabe, R, Nakajima, T et al. (2001). Successful treatment of dry eye in two patients with chronic graft-versushost disease with systemic administration of FK506 and corticosteroids. Cornea 20: 430-434.
11. Kurt, RA, Yalçindag, N, Atilla, H and Arat, M (2009). Topical cyclosporine-A in dry eye associated with chronic graft versus host disease. Ann Ophthalmol (Skokie) 41: 166-169.
12. Couriel, DR, Saliba, R, Escalón, MP, Hsu, Y, Ghosh, S, Ippoliti, C et al. (2005). Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 130: 409-417.
13. Johnston, LJ, Brown, J, Shizuru, JA, Stockerl-Goldstein, KE, Stuart, MJ, Blume, KG et al. (2005). Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 11: 47-55.
14. Inagaki, J, Nagatoshi, Y, Hatano, M, Isomura, N, Sakiyama, M and Okamura, J (2008). Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. Bone Marrow Transplant 41: 571-577.
15. Niethammer, D, Kümmerle-Deschner, J and Dannecker, GE (1999). Side-effects of long-term immunosuppression versus morbidity in autologous stem cell rescue: striking the balance. Rheumatology (Oxford) 38: 747-750.
16. Nauta, AJ and Fibbe, WE (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood 110: 3499-3506.
17. Bassi, EJ, Aita, CA and Câmara, NO (2011). Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand? World J Stem Cells 3: 1-8.
18. Bernardo, ME, Cometa, AM and Locatelli, F (2012). Mesenchymal stromal cells: a novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation? Bone Marrow Transplant 47: 323-329.
19. Ogawa, Y, Shimmura, S, Kawakita, T, Yoshida, S, Kawakami, Y and Tsubota, K (2009). Epithelial mesenchymal transition in human ocular chronic graft-versus-host disease. Am J Pathol 175: 2372-2381.
20. Pflugfelder, SC (2004). Antiinflammatory therapy for dry eye. Am J Ophthalmol 137: 337-342.
21. Brignole, F, Pisella, PJ, Goldschild, M, De Saint Jean, M, Goguel, A and Baudouin, C (2000). Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci 41: 1356-1363.
22. Di Ianni, M, Del Papa, B, De Ioanni, M, Moretti, L, Bonifacio, E, Cecchini, D et al. (2008). Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 36: 309-318.
23. Prevosto, C, Zancolli, M, Canevali, P, Zocchi, MR and Poggi, A (2007). Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92: 881-888.
24. Chen, X, Armstrong, MA and Li, G (2006). Mesenchymal stem cells in immunoregulation. Immunol Cell Biol 84: 413-421.
25. Krampera, M, Pizzolo, G, Aprili, G and Franchini, M (2006). Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone 39: 678-683.
26. Nakashima, H (2007). Membranous nephropathy is developed under Th2 environment in chronic graft-versus-host disease. Med Hypotheses 69: 787-791.
27. Aggarwal, S and Pittenger, MF (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815-1822.
28. Ogawa, Y, Kuwana, M, Yamazaki, K, Mashima, Y, Yamada, M, Mori, T et al. (2003). Periductal area as the primary site for T-cell activation in lacrimal gland chronic graftversus- host disease. Invest Ophthalmol Vis Sci 44: 1888-1896.
29. Clark, FJ, Gregg, R, Piper, K, Dunnion, D, Freeman, L, Griffiths, M et al. (2004). Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 103: 2410-2416.
30. Shevach, EM (2002). CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2: 389-400.
31. Poggi, A and Zocchi, MR (2008). Role of bone marrow stromal cells in the generation of human CD8+ regulatory T cells. Hum Immunol 69: 755-759.
32. Ciubotariu, R, Colovai, AI, Pennesi, G, Liu, Z, Smith, D, Berlocco, P et al. (1998). Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+CD28- regulatory T cells. J Immunol 161: 5193-5202.
33. Zeiser, R, Nguyen, VH, Beilhack, A, Buess, M, Schulz, S, Baker, J et al. (2006). Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108: 390-399.
34. Ellison, CA, Bradley, DS, Fischer, JM, Hayglass, KT and Gartner, JG (2002). Murine graft-versus-host disease induced using interferon-gamma- deficient grafts features antibodies to double-stranded DNA, T helper 2-type cytokines and hypereosinophilia. Immunology 105: 63-72.
35. Kataoka, Y, Iwasaki, T, Kuroiwa, T, Seto, Y, Iwata, N, Hashimoto, N et al. (2001). The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease. Immunology 103: 310-318.
36. Liu, Z, Tugulea, S, Cortesini, R and Suciu-Foca, N (1998). Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+CD28- T cells. Int Immunol 10: 775-783.
37. The International Dry Eye WorkShop (2007). The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf 5: 75-92.
38. Pavletic, SZ, Martin, P, Lee, SJ, Mitchell, S, Jacobsohn, D, Cowen, EW et al. (2006). Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 12: 252-266.
39. Le Blanc, K, Frassoni, F, Ball, L, Locatelli, F, Roelofs, H, Lewis, I et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versushost disease: a phase II study. Lancet 371: 1579-1586.
40. von Bonin, M, Stölzel, F, Goedecke, A, Richter, K, Wuschek, N, Hölig, K et al. (2009). Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 43: 245-251.
41. Schiffman, RM, Christianson, MD, Jacobsen, G, Hirsch, JD and Reis, BL (2000). Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 118: 615-621.
42. Bron, AJ (2001). Diagnosis of dry eye. Surv Ophthalmol 45 Suppl 2: S221-S226.
43. Wang, Y, Ogawa, Y, Dogru, M, Kawai, M, Tatematsu, Y, Uchino, M et al. (2008). Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant 41: 293-302.